Literature DB >> 4335442

Phenobarbital-induced alterations in vitamin D metabolism.

T J Hahn, S J Birge, C R Scharp, L V Avioli.   

Abstract

The metabolic fate of intravenously injected vitamin D(3)-1,2-(3)H (D(3)-(3)H) was studied in two normal individuals on chronic phenobarbital therapy. Silicic acid column chromatography of lipid-soluble plasma extracts obtained serially for 96 hr after D(3)-(3)H injection demonstrated a decreased plasma D(3)-(3)H half-life and increased conversion to more polar metabolites. The polar metabolites formed included several with chromatographic mobility similar to known biologically inactive vitamin D metabolites and one with chromatographic mobility identical to 25-hydroxycholecalciferol. Disappearance of this latter material was also accelerated. A child with rickets and a normal volunteer studied before and after a 2 wk course of phenobarbital therapy demonstrated similar alterations in D(3)-(3)H metabolism. When liver microsomes from 3-wk-old Sprague-Dawley rats treated with phenobarbital were incubated with D(3)-(3)H, polar metabolites were produced with chromatographic mobility similar to the plasma D(3)-(3)H metabolites from phenobarbital-treated humans. Similar incubations employing 25-hydroxy-cholecalciferol-26-27-(3)H as the substrate also demonstrated an increased conversion to polar metabolites. The data suggest that the reported increased incidence of osteomalacia observed in patients on chronic anticonvulsant therapy may be the result of an accelerated conversion of vitamin D and its active metabolite, 25-hydroxycholecalciferol, to polar metabolites by druginduced liver microsomal enzymes.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4335442      PMCID: PMC302186          DOI: 10.1172/JCI106868

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Effect of phenobarbital and other drugs on the metabolism and uterotropic action of estradiol-17-beta and estrone.

Authors:  W Levin; R M Welch; A H Conney
Journal:  J Pharmacol Exp Ther       Date:  1968-02       Impact factor: 4.030

2.  Decreased central depressant effect of progesterone and other steroids in rats pretreated with drugs and insecticides.

Authors:  A H Conney; M Jacobson; W Levin; K Schneidman; R Kuntzman
Journal:  J Pharmacol Exp Ther       Date:  1966-11       Impact factor: 4.030

3.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

4.  [Osteopathies in antiepileptic long-term therapy (preliminary report)].

Authors:  R Kruse
Journal:  Monatsschr Kinderheilkd       Date:  1968-06

Review 5.  Drugs and enzyme induction.

Authors:  R Kuntzman
Journal:  Annu Rev Pharmacol       Date:  1969       Impact factor: 13.820

6.  The association of a metabolite of vitamin D3 with intestinal mucosa chromatin in vivo.

Authors:  M R Haussler; J F Myrtle; A W Norman
Journal:  J Biol Chem       Date:  1968-08-10       Impact factor: 5.157

7.  Biologically active metabolite of vitamin D3 from bone, liver, and blood serum.

Authors:  J Lund; H F DeLuca
Journal:  J Lipid Res       Date:  1966-11       Impact factor: 5.922

8.  Effect of chronic phenobarbital treatment on the liver microsomal metabolism and uterotropic action of 17-beta-estradiol.

Authors:  W Levin; R M Welch; A H Conney
Journal:  Endocrinology       Date:  1967-01       Impact factor: 4.736

9.  Stimulatory effect of N-phenylbarbital (phetharbital) on cortisol hydroxylation in man.

Authors:  R Kuntzman; M Jacobson; W Levin; A H Conney
Journal:  Biochem Pharmacol       Date:  1968-04       Impact factor: 5.858

10.  Metabolism of vitamin D3-3H in human subjects: distribution in blood, bile, feces, and urine.

Authors:  L V Avioli; S W Lee; J E McDonald; J Lund; H F DeLuca
Journal:  J Clin Invest       Date:  1967-06       Impact factor: 14.808

View more
  54 in total

1.  Effects of anticonvulsants and inactivity on bone disease in epileptics.

Authors:  L E Murchison; P D Bewsher; M Chesters; J Gilbert; G Catto; E Law; E McKay; H S Ross
Journal:  Postgrad Med J       Date:  1975-01       Impact factor: 2.401

2.  The clinical consequences of chronic hepatic enzyme induction by anticonvulsant drugs.

Authors:  A Richens
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Anticonvulsant osteomalacia.

Authors: 
Journal:  Br Med J       Date:  1976-12-04

4.  Actions of vitamins D2 and D3 and 25-OHD3 in anticonvulsant osteomalacia.

Authors:  C Christiansen; P Rodbro; O Munck
Journal:  Br Med J       Date:  1975-05-17

Review 5.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro.

Authors:  T J Hahn; C R Scharp; C A Richardson; L R Halstead; A J Kahn; S L Teitelbaum
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose.

Authors:  R G Klein; S B Arnaud; J C Gallagher; H F Deluca; B L Riggs
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

8.  Anticonvulsant osteomalacia induced in the rat by diphenylhydantoin.

Authors:  M Harris; D J Rowe; A J Darby
Journal:  Calcif Tissue Res       Date:  1978-02-28

9.  [The frequency of adult anticonvulsant osteomalacia in relation to duration of therapy and dosage of anticonvulsants (author's transl)].

Authors:  U Mehregan; K H Krause; P Prager
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979-04-12

10.  Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.

Authors:  T J Hahn; L R Halstead; S L Teitelbaum; B H Hahn
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.